Thread by @ProvectusBio

$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens from a defined library; PV-10 produces antigens present in an injected tumor that may extend beyond what's contained in the library

$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA presumably is based on genomic profiling of a single tumor; PV-10 produces antigens specific to each injected tumor

$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens, but presumably does not produce co-stimulatory factors; PV-10 produces antigens + multiple co-stimulatory factors, such as DAMPs (damage-associated molecular patterns)

$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigenic material without the context of the TME (tumor microenvironment); PV-10 produces antigens from within the TME

1/ Continuing our thread about what we believe are the differences between $PVCT’s intratumoral (ITU) PV-10 cancer immunotherapy and $MRNA intramuscular (IM) mRNA-4157 cancer vaccine. #rosebengal #rosebengalsodium.

2/ The Venn diagrams below illustrate the immune activation potential as a proportion of the total available drivers of anti-tumor activation of [LEFT] $MRNA’s IM mRNA-4157 [yellow] and [RIGHT] $PVCT’s ITU PV-10 [magenta].

3/ $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #1: the extent of tumor epitopes sampled when creating mRNA-4157 from and for a patient vs the extent sampled when injecting multiple tumors of each and every patient with PV-10.

4/ $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #2: the single mode of activation (i.e., only antigen production) by mRNA-4157 vs an orchestrated, multimodal activation (i.e., release of tumor antigens & immune upregulating agents) by PV-10.

5/a $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #3: $MRNA’s mRNA-4157 activation is divorced from the context of actual tumor tissue. mRNA-4157 is administered intramuscularly, which is not necessarily proximate to tumor tissue.

5/b Whereas, the signaling resulting from $PVCT’s ITU PV-10 is released from actual tumor because the actual tumor is injected with PV-10. #rosebengal #rosebengalsodium.

5/c Impacting actual tumor tissue (by $PVCT’s ITU PV-10’s injection) is likely to have secondary influence on the recruitment of immune components (such as dendritic cells) and effective training of an adaptive response (i.e., functional CD8+ T cells) against tumor.

6a/ The illustrations below endeavor to characterize what appears to be the one-size-fits-all nature of $MRNA’s IM mRNA-4157 [LEFT], which is precisely matched to a subset of potential immune markers from a specific tumor, compared to $PVCT’s ITU PV-10 [RIGHT].

6b/ $MRNA’s IM mRNA-4157’s precision may actually compromise activity against other tumor epitopes (i.e., genomic variants, which are represented by different size nuts in the LEFT illustration).

6c/ In contrast, by deploying $PVCT’s ITU PV-10 against a broad range of a patient's tumor burden (the RIGHT illustration), precise education of the immune system to produce T cells functional against each injected tumor epitope is possible.

7/ $PVCT’s ITU PV-10 seems more personalized, more precise… #rosebengal #rosebengalsodium. #PrecisionMedicine.

@threadreaderapp unroll